Cue Biopharma, Inc. (CUE)Healthcare | Biotechnology | Boston, United States | NasdaqCM
0.61 USD
-0.01
(-1.463%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 0.61 +0.00 (0.049%) ⇧ (April 17, 2026, 7:54 p.m. EDT) Short-term: ★★★☆☆ | Long-term: ★★☆☆☆ | Dividends: ★☆☆☆☆ |
Hot Take | April 19, 2026, midnight EDT
Despite a fundamentally valueless profile with negative earnings, gross margins, and a neutral dividend, CUE is positioned for a high-risk, high-reward trade driven entirely by Boehringer Ingelheim pipeline data. The retail sentiment is currently optimistic, supported by a 'strong buy' consensus despite the lack of tangible revenue generation. The options market is pricing in a massive upside move to $1.00+ based on this partnership, but this leaves the long-term investment thesis on shaky ground given the lack of operational cash flow, making it a pure 'knowledge plays' lottery ticket rather than a solid long-term asset. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.173234 |
| AutoETS | 0.333459 |
| AutoARIMA | 0.333464 |
| MSTL | 0.339665 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 10% |
| H-stat | 25.78 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 5.83 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 15.878 |
| Revenue per Share | 0.29 |
| Market Cap | 59,201,972 |
| Forward P/E | -1.26 |
| Beta | 1.58 |
| Profit Margins | -96.85% |
| Website | https://www.cuebiopharma.com |
As of April 19, 2026, midnight EDT: Options activity is highly asymmetric and skewed toward calls. Call OI is concentrated heavily at the $1.00 strike (up to 2.6k contracts), implying a significant speculative distribution of directional bets for a 50% rise. However, the $1.00 strike represents deep Out-of-the-Money (OTM) territory relative to the current price of $0.61, suggesting this positioning is for a binary breakthrough or setup rather than immediate normalization. Put writing exists but is minimal compared to call exposure, indicating a bullish outlook based on expected R&D milestones (Boehringer Ingelheim data), despite a lack of immediate near-term catalysts priced in the OTM calls.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.22407168 |
| Address1 | 40 Guest Street |
| All Time High | 31.69 |
| All Time Low | 0.166 |
| Ask | 0.6086 |
| Ask Size | 19 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 46,427,480 |
| Average Daily Volume3 Month | 8,787,645 |
| Average Volume | 8,787,645 |
| Average Volume10Days | 46,427,480 |
| Beta | 1.578 |
| Bid | 0.6061 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 0.274 |
| City | Boston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.6062 |
| Current Ratio | 2.741 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 0.705 |
| Day Low | 0.5717 |
| Debt To Equity | 15.878 |
| Display Name | Cue Biopharma |
| Earnings Call Timestamp End | 1,724,099,400 |
| Earnings Call Timestamp Start | 1,724,099,400 |
| Earnings Timestamp End | 1,755,547,200 |
| Earnings Timestamp Start | 1,755,028,800 |
| Ebitda | -25,563,000 |
| Ebitda Margins | -0.93071 |
| Enterprise To Ebitda | -1.376 |
| Enterprise To Revenue | 1.28 |
| Enterprise Value | 35,169,972 |
| Eps Forward | -0.48 |
| Eps Trailing Twelve Months | -0.28 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.31156 |
| Fifty Day Average Change | 0.29463997 |
| Fifty Day Average Change Percent | 0.94569254 |
| Fifty Two Week Change Percent | -22.407167 |
| Fifty Two Week High | 1.03 |
| Fifty Two Week High Change | -0.4238 |
| Fifty Two Week High Change Percent | -0.41145632 |
| Fifty Two Week Low | 0.166 |
| Fifty Two Week Low Change | 0.44019997 |
| Fifty Two Week Low Change Percent | 2.651807 |
| Fifty Two Week Range | 0.166 - 1.03 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,514,903,400,000 |
| Float Shares | 97,070,920 |
| Forward Eps | -0.48 |
| Forward P E | -1.2629167 |
| Free Cashflow | -9,951,750 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 29 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | -0.26859 |
| Gross Profits | -7,377,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00565 |
| Held Percent Institutions | 0.22312 |
| Implied Shares Outstanding | 97,660,791 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a bifunctional fusion protein designed to promote immune tolerance by inducing iTregs from Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinical trial to treat HPV+ recurrent metastatic, or head and neck squamous cell carcinoma in second line, and beyond patients as a monotherapy, as well as in phase 1b clinical trial for the treatment of head and neck squamous cell carcinoma as a first line, therapy in combination with standard of care KEYTRUDA; and CUE-102, which is in phase 1b clinical trial as a monotherapy in late line recurrent metastatic WT1+ colorectal, gastric, ovarian, and pancreatic cancer. It has collaboration agreements with LG Chem, Ltd. for the development of CUE-101 and CUE-102 Immuno-STATs; collaboration and option agreement with Ono Pharmaceutical Co., Ltd to development and commercialization rights for CUE-401; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts. |
| Long Name | Cue Biopharma, Inc. |
| Market | us_market |
| Market Cap | 59,201,972 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_417883814 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -26,602,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 59,201,971 |
| Number Of Analyst Opinions | 1 |
| Open | 0.64 |
| Operating Cashflow | -21,687,000 |
| Operating Margins | 0.08924 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 617 949 2680 |
| Post Market Change | 0.00030004978 |
| Post Market Change Percent | 0.049496833 |
| Post Market Price | 0.6065 |
| Post Market Time | 1,776,470,065 |
| Previous Close | 0.6152 |
| Price Hint | 4 |
| Price To Book | 2.2124088 |
| Price To Sales Trailing12 Months | 2.155464 |
| Profit Margins | -0.96853995 |
| Quick Ratio | 2.644 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.009 |
| Regular Market Change Percent | -1.46294 |
| Regular Market Day High | 0.705 |
| Regular Market Day Low | 0.5717 |
| Regular Market Day Range | 0.5717 - 0.705 |
| Regular Market Open | 0.64 |
| Regular Market Previous Close | 0.6152 |
| Regular Market Price | 0.6062 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 2,868,302 |
| Return On Assets | -0.44556 |
| Return On Equity | -1.2110801 |
| Revenue Growth | 12.923 |
| Revenue Per Share | 0.29 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 4 |
| Shares Outstanding | 97,660,791 |
| Shares Percent Shares Out | 0.0273 |
| Shares Short | 2,664,499 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 1,781,535 |
| Short Name | Cue Biopharma, Inc. |
| Short Percent Of Float | 0.0274 |
| Short Ratio | 1.15 |
| Source Interval | 15 |
| State | MA |
| Symbol | CUE |
| Target High Price | 4.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 4.0 |
| Target Median Price | 4.0 |
| Total Cash | 28,229,000 |
| Total Cash Per Share | 0.289 |
| Total Debt | 4,197,000 |
| Total Revenue | 27,466,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.28 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.56114 |
| Two Hundred Day Average Change | 0.04505998 |
| Two Hundred Day Average Change Percent | 0.08030078 |
| Type Disp | Equity |
| Volume | 2,868,302 |
| Website | https://www.cuebiopharma.com |
| Zip | 2,135 |